{"ok":true,"nota":{"id":"e60e5e265d67129c","slug":"una-proteina-en-sangre-sigue-la-etapa-del-alzheimer-pero-no-alcanza-pa-e60e5e","titulo":"Una proteína en sangre sigue la etapa del Alzheimer, pero no alcanza para diagnosticar solo","resumen":"Investigadores midieron en sangre una proteína asociada al daño por tau en personas con deterioro subjetivo, deterioro leve y demencia por Alzheimer. Compararon sus niveles con otros marcadores y con la presencia del gen APOE4 para ver cómo cambian a lo largo de la enfermedad.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Michaelian, J. C., Yu, R., Lee, A., Karikari, T. K., Shi, L., Drummond, E., Naismith, S. L.","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366056v1?rss=1","imagen":"/hoy/portada/e60e5e265d67129c","tema":"salud","subtemas":["alzheimer","biomarcadores","demencia","análisis de sangre","deterioro cognitivo"],"entidades":["Alzheimer","APOE4","tau","medRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-24T00:00:00.000Z","indexTs":"2026-10-24T16:27:13.955Z","hash":"fe4e108824377f8afd3b564a213e2f239639b8a652c36f7fd867d5fce1e15d85","tsa":{"time":"Oct 24 16:28:00 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"motor","registro":"hallazgo","porQueImporta":"Un análisis de sangre que acompañe la progresión podría reducir la necesidad de estudios más costosos y invasivos para seguir a un paciente. Para quien tiene un familiar con síntomas de memoria, eso significa más chances de saber en qué etapa está sin pasar por una punción lumbar. Pero el estudio no demuestra todavía que prediga con precisión quién va a empeorar, y ese es el paso que falta para que sirva en la consulta cotidiana.","quienFirma":"medRxiv (preprint; institución principal no identificada en el extracto)","confianza":"preprint","consulta":{"pregunta":"¿Te harías un análisis de sangre para detectar Alzheimer?"}},"sello":{"hash":"fe4e108824377f8afd3b564a213e2f239639b8a652c36f7fd867d5fce1e15d85","sello":"89e3a491f67db38a641d1fb0773b67a01cf0a1d5631c6268ec5198d6a7b5e9b2","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6580941,"aleatorio":"569a6d14a17bcc63dfb56728ed9891ce2f6d709c28f85f634a2a00169794082e","tiempo":"2026-10-24T16:27:30.000Z"},"nist":{"cadena":2,"pulso":1997664,"salida":"1DC1537A6019D5A1F1814580669DA98F771591D482822D2AE01E16CD05DDDA04CB23793AAC36D0627B9ED52DE5568FC5EFA7F21FCC50B397FA952CA4E4ECDF10","tiempo":"2026-10-24T16:27:00.000Z"},"noAntes":"2026-10-24T16:27:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 24 16:28:00 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Plasma eMTBR-tau as a marker of clinical stage and progression across the Alzheimer's disease continuum","descripcion":"Importance: Plasma biomarkers of neurodegeneration may help characterise progression across the Alzheimer's disease (AD) continuum. Plasma eMTBR-tau243 has been associated with tau pathology and cognitive decline. Whether plasma eMTBR-tau levels differ across subjective cognitive decline (SCD), mild cognitive impairment (MCI) and AD dementia, between MCI subtypes, or best discriminate subsequent clinical progression in brain health and memory clinic populations remains unclear. Objective: To compare plasma eMTBR-tau and selected biomarkers of neurodegeneration, neuropathology, and neuroinflammation across the AD continuum by pTau217 and APOE {epsilon}4 status, and explore their associations ","pubDate":"2026-10-24","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366056v1?rss=1"},"indexado":"2026-10-24T16:27:13.955Z"}}